Sprint Bioscience (Q4 Review): Promising development - Redeye
Redeye returns with an update on Sprint Bioscience following recent events and the Q4 report. We go through key events for 2025 and look a bit further into the company's business model. We raise our valuation.
ANNONS
Redeye returns with an update on Sprint Bioscience following recent events and the Q4 report. We go through key events for 2025 and look a bit further into the company's business model. We raise our valuation.
